Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices

References

• Lebrec D, Nouel O, Corbic M, et al. Propranolol-a medical treatment for portal hypertension? Lancet. 1980;2:180–182.
   PubMed Web of Science ®Google Scholar
• Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med. 1991;324:1532–1538.
   PubMed Web of Science ®Google Scholar
• de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.
   PubMed Web of Science ®Google Scholar
• Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997;25:63–70.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911–921.
   PubMed Web of Science ®Google Scholar
• Madsen BS, Havelund T, Krag A. 2013. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv Ther. 30:659–670.
   PubMed Web of Science ®Google Scholar
• Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–582.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–1641.
   PubMed Web of Science ®Google Scholar
• Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–582.
   PubMed Web of Science ®Google Scholar
• Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017–1022.
   PubMed Web of Science ®Google Scholar
• Leithead JA, Rajoriya N, Tehami N, et al. . Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2015;64:1111–1119.
   PubMed Web of Science ®Google Scholar
• Bossen L, Krag A, Vilstrup H, et al. 2015. Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients. Hepatology. 2016;63:1968–1976.
   Web of Science ®Google Scholar
• Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–1690.
   PubMed Web of Science ®Google Scholar
• Bucsics T, Mandorfer M, Schwabl P, et al. Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: a retrospective cohort study. J Gastroenterol Hepatol. 2015;30:1657–1665.
   PubMed Web of Science ®Google Scholar
• Serste T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–799.
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Burroughs AK, et al. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79:53–55.
   PubMed Web of Science ®Google Scholar
• Ferlitsch M, Reiberger T, Hoke M, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56:1439–1447.
   PubMed Web of Science ®Google Scholar
• Ferlitsch A, Bota S, Paternostro R, et al. Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient. Liver Int. 2015;35:2115–2120.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.
   PubMed Web of Science ®Google Scholar
• Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Rognant N, Lemoine S. Evaluation of renal function in patients with cirrhosis: where are we now? World J Gastroenterol. 2014;20:2533–2541.
   PubMed Web of Science ®Google Scholar
• Angeli P, Gines P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62:968–974.
   PubMed Web of Science ®Google Scholar
• Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med. 1987;317:856–861.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Balanzo J. 2008. Variceal bleeding : pharmacological treatment and prophylactic strategies. Drugs. 68:2303–2324.
   PubMed Web of Science ®Google Scholar
• D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.
   PubMed Web of Science ®Google Scholar
• Caregaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994;154:201–205.
   PubMed Web of Science ®Google Scholar
• Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Albillos A, Genesca J, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63:197–206.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective beta-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012;47:561–568.
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107:418–427.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37:902–908.
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G. Beta blockers in cirrhosis: the window re-opens. J Hepatol. 2016;64:532–534.
   PubMed Web of Science ®Google Scholar